- Home
- VYGR vs MFIN Comparison
VYGR vs MFIN Comparison
Compare VYGR & MFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYGR
- MFIN
- Stock Information
- Founded
- VYGR 2013
- MFIN 1995
- Country
- VYGR United States
- MFIN United States
- Employees
- VYGR N/A
- MFIN N/A
- Industry
- VYGR Biotechnology: Pharmaceutical Preparations
- MFIN Finance: Consumer Services
- Sector
- VYGR Health Care
- MFIN Finance
- Exchange
- VYGR Nasdaq
- MFIN Nasdaq
- Market Cap
- VYGR 206.9M
- MFIN 223.8M
- IPO Year
- VYGR 2015
- MFIN 1996
- Fundamental
- Price
- VYGR $4.24
- MFIN $10.71
- Analyst Decision
- VYGR Strong Buy
- MFIN Strong Buy
- Analyst Count
- VYGR 7
- MFIN 1
- Target Price
- VYGR $14.50
- MFIN $12.00
- AVG Volume (30 Days)
- VYGR 678.8K
- MFIN 42.9K
- Earning Date
- VYGR 08-06-2025
- MFIN 10-28-2025
- Dividend Yield
- VYGR N/A
- MFIN 4.48%
- EPS Growth
- VYGR N/A
- MFIN N/A
- EPS
- VYGR N/A
- MFIN 1.75
- Revenue
- VYGR $42,580,000.00
- MFIN $332,256,000.00
- Revenue This Year
- VYGR N/A
- MFIN N/A
- Revenue Next Year
- VYGR $107.07
- MFIN $1.53
- P/E Ratio
- VYGR N/A
- MFIN $6.12
- Revenue Growth
- VYGR N/A
- MFIN 16.48
- 52 Week Low
- VYGR $2.65
- MFIN $7.40
- 52 Week High
- VYGR $8.28
- MFIN $10.98
- Technical
- Relative Strength Index (RSI)
- VYGR 70.98
- MFIN 60.53
- Support Level
- VYGR $3.32
- MFIN $10.27
- Resistance Level
- VYGR $3.49
- MFIN $10.73
- Average True Range (ATR)
- VYGR 0.23
- MFIN 0.27
- MACD
- VYGR 0.06
- MFIN 0.00
- Stochastic Oscillator
- VYGR 94.03
- MFIN 80.95
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
About MFIN Medallion Financial Corp.
Medallion Financial Corp is a finance company that originates and services loans in various industries. The five operating segments are, (1) recreation, (2) home improvement, (3) commercial, (4) taxi medallion, and (5) strategic partnership loans. The company generates maximum revenue from the Recreation segment.